Company / Accounts Receivable
vTv Therapeutics Inc. Accounts Receivable History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$102.0K
FY2023
5-year range
$57.0K / $173.0K
FY2019-FY2023
Trend
-41.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 7 years, ranging from $0 in FY2017 to $173,000 in FY2022.
Based on SEC 10-K filings.
$102,000 in FY2023 with a 3-year CAGR of -13.6%.
Improved from $57,000 to $102,000 over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -13.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -13.6%, indicating a declining trend.
- In FY2023, accounts receivable decreased 41.0% year-over-year.
- Peak accounts receivable was recorded in FY2022.
- Lowest accounts receivable in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $102.0K | -41.0% |
| FY2022 | $173.0K | +203.5% |
| FY2021 | $57.0K | -63.9% |
| FY2020 | $158.0K | +3060.0% |
| FY2019 | $5.0K | - |
| FY2018 | - | - |
| FY2017 | $0 | - |
| FY2016 | $0 | -100.0% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026